Live tape
Top 8, mentions 7d7,424SPCX1,449 mentions▲ +0.09GOOGL1,363 mentions▲ +0.05NVDA1,206 mentions▲ +0.09MSFT853 mentions▲ +0.04QQQ702 mentions▲ +0.08META650 mentions▲ +0.04SPY603 mentions▲ +0.06AMZN598 mentions▲ +0.07

Equity · Healthcare

KRYS

NASDAQ

Krystal Biotech, Inc.

$346 −0.60% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 10, 2026
Price · Chart
39 sessions
$380 $300 13 Jul 10 Sep

The line runs $363.03 on 13 July through $346 on 10 September, on a scale from $300 to $380. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 39 sessions, 13 Jul – 10 Sep 2026
Market cap $10.2B
P/E (TTM) 43.4
52-week range $137.45 – $378.20
Avg volume 37.5K

as of Sep 10, 2026

KRYS insider trades

SEC Form 4 · last 90 days · newest reported trade 4 Sep 2026
Open-market buys 0
Open-market sells 3
Net sold $26.19M
Non-trade filings 1
Date Insider Type Shares Value
04 Sep 2026 Krishnan Krish S President and CEO Sell 25,000 $8.98M
04 Sep 2026 Krishnan Suma President, R&D Sell 25,000 $8.98M
14 Aug 2026 ROSSI DINO A Director Sell 25,000 $8.23M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
14 Aug 2026 ROSSI DINO A Director Gift 3,691

KRYS reported financials

SEC EDGAR XBRL SEC EDGAR

KRYS reported revenue of $389.1M for the fiscal year ended 31 Dec 2025. Net income over the same period was $204.8M.

Figure Reported Period
Revenue $389.1M 31 Dec 2025 fiscal year
Net income $204.8M 31 Dec 2025 fiscal year
Diluted EPS $6.84 31 Dec 2025 fiscal year
Total assets $1.5B 30 Jun 2026 at period end
Total equity $1.4B 30 Jun 2026 at period end

KRYS earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $1.79 $119M
31 Mar 2026 Q1 2026 $1.83 $116M
31 Dec 2025 FY 2025 $6.84 $389M
30 Sep 2025 Q3 2025 $2.66 $98M
30 Jun 2025 Q2 2025 $1.29 $96M
31 Mar 2025 Q1 2025 $1.20 $88M
31 Dec 2024 FY 2024 $3.00 $291M
30 Sep 2024 Q3 2024 $0.91 $84M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

KRYS institutional holders

SEC Form 13F SEC EDGAR

6 of the 45 institutional funds we track reported a KRYS position for the quarter ended 30 Jun 2026 — a combined $61.2M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Renaissance Technologies Added +521.7% shares 59,680 $22.2M
Bridgewater Associates Held (±25%) +17.5% shares 54,489 $20.3M
Fisher Asset Management Held (±25%) −0.4% shares 27,676 $10.3M
AQR Capital Management Held (±25%) −0.8% shares 14,002 $5.2M
Two Sigma Investments New position 6,084 $2.3M
Citadel Advisors Held (±25%) −0.0% shares 2,725 $1.0M
D. E. Shaw & Co. Exited
Marshall Wace Exited
Millennium Management Exited
Tudor Investment Corp Exited

KRYS fails-to-deliver

SEC CNS data SEC

On 09 Sep 2026, 7,408 shares of KRYS failed to deliver (about $2.6M).

Settlement date Shares failed Notional % of shares out
09 Sep 2026 7,408 $2.6M 0.025%
04 Sep 2026 203 $75K 0.001%
03 Sep 2026 643 $237K 0.002%
01 Sep 2026 231 $83K 0.001%

Congressional trades in KRYS

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in KRYS is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.

Date Member Type Amount
12 Dec 2022 filed 20 Jan 2023 Sara Jacobs house · Democrat–CA Purchase $1K–$15K

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings